February 2010

Strategies for Treatment With Anti–Tumor Necrosis Factor Agents in PsoriasisMaintaining Efficacy and Safety for the Long Haul

Author Affiliations

Author Affiliations: Division of Dermatology, NorthShore University HealthSystem, Skokie, Illinois (Drs Gordon and Gandhi); and Division of Dermatology, University of Chicago, Pritzker School of Medicine, Chicago, Illinois (Dr Gordon).


Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010

Arch Dermatol. 2010;146(2):186-188. doi:10.1001/archdermatol.2009.394

Psoriasis is a very common, chronic, immune-mediated disease that commonly presents in young patients. Owing to the high level of physical, emotional, and economic disability associated with moderate to severe psoriasis and the long-term nature of the disease, many patients require long-term treatment. Often for these patients, treatments with local therapies, including topical agents and UV-B phototherapy, are insufficient for long-term relief from their disease. Much of the clinical research in psoriasis over the past 2 decades has been dedicated to finding systemic medications to treat those who need long-term control of extensive disease.

First Page Preview View Large
First page PDF preview
First page PDF preview